The Interplay of Autoimmune Disease, Cancer, and Immunity: Current Understanding and Therapeutic Prospects
-
Tayyab Shafiq
,
Syeda Mahnoor Bukhari
,
Arneeb Zahra
,
Hafiza Sana Mahek
,
Hira Tariq
,
Waseem Sajjad
Abstract
Background: In light of chronic inflammation and dysregulated immune responses, autoimmune disorders and cancer are closely related. It is essential to comprehend how they interact in order to create immunotherapeutic techniques that work.
Materials and Methods: The purpose of this review is to summarize the most recent research on the relationship between immunology, cancer, and autoimmune illnesses and to assess new treatment strategies that target each of these diseases. PubMed, MEDLINE, the Cochrane Library, Embase, and Scopus were used in a methodical search (2010–2023). Studies evaluating immunotherapy results, immunological processes, and cancer incidence in patients with autoimmune diseases were all eligible. Using random-effects meta-analysis, the data were examined.
Results: A total of 78,456 patients from fifty-seven studies were examined. Patients with autoimmune diseases had a considerably higher risk of developing cancer (OR = 1.58; 95% CI: 1.42–1.76; p < 0.001), frequently as a result of immunosuppressive treatment and persistent inflammation. Among the common mechanisms were increased pro-inflammatory cytokines (TNF-α, IL-6) and dysregulation of immunological checkpoints (PD-1/PD-L1). Although cytokine blockers and checkpoint inhibitors have demonstrated effectiveness, they also carry significant hazards.
Conclusion: The confluence of immune regulation, cancer, and autoimmunity brings to light both treatment possibilities and difficulties. Future studies should concentrate on tailoring immunotherapies to optimize their positive effects while reducing their negative ones.
2. Klöß S, Dehmel S, Braun A, et al. From cancer to immune-mediated diseases and tolerance induction: lessons learned from immune oncology and classical anti-cancer treatment. Front Immunol. 2020:11:1423.
3. Mangani D, Yang D, Anderson AC. Learning from the nexus of autoimmunity and cancer. Immunity. 2023; 56(2): 256-271.
4. Antonatos C, Panoutsopoulou M, Georgakilas GK, et al. Gene expression meta-analysis of potential shared and unique pathways between autoimmune diseases under anti-TNFα therapy. Genes(Basel). 2022; 13(5): 776.
5. Xiang Y, Zhang M, Jiang D, et al. The role of inflammation in autoimmune disease: a therapeutic target. Front Immunol. 2023; 14: 1267091.
6. Ogino S, Nowak JA, Hamada T, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut. 2018; 67(6): 1168-1180.
7. Cai X, Zhan H, Ye Y, et al. Current progress and future perspectives of immune checkpoint in cancer and infectious diseases. Front Genet. 2021; 12:785153.
8. Kumar AR, Devan AR, Nair B, et al. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Mol Biol Rep. 2021;48(12):8075-8095.
9. De Santis M, Selmi C. The therapeutic potential of epigenetics in autoimmune diseases. Clin Rev Allergy Immunol. 2012;42(1):92-101.
10. Hawsawi YM, Al-Zahrani F, Mavromatism CH, et al. Stem cell applications for treatment of cancer and autoimmune diseases: its promises, obstacles, and future perspectives. Technol Cancer Res Treat. 2018:17:1533033818806910.
11. Roufas C, Chasiotis D , Makris A, et al. The expression and prognostic impact of immune cytolytic activity-related markers in human malignancies: a comprehensive meta-analysis. Front Oncol. 2018:8:27.
12. Logotheti S, Pützer BM. STAT3 and STAT5 targeting for simultaneous management of melanoma and autoimmune diseases. Cancers (Basel). 2019; 11(10):1448.
13. Granito A, Muratori L, Lalanne C, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021;27(22):2994-3009.
14. Zeng Z, Chew HY, Cruz JG, et al. Investigating T cell immunity in cancer: achievements and prospects. Int J Mol Sci. 2021;22(6):2907
15. Cristaldi, E. et al. A possible link between autoimmunity and cancer. In Autoimmune disorders – pathogenic aspects 387–417 (2011).
16. Gaissmaier L, Christopoulos P. Immune modulation in lung cancer: Current concepts and future strategies. Respiration. 2020:1-27.
17. Hossen MM, Ma Y, Yin ZH, et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol. 2023; 14:1198365.
18. Popov J, Caputi V, Nandeesha N, et al. Microbiota-immune interactions in ulcerative colitis and colitis associated cancer and emerging microbiota-based therapies. Int J Mol Sci. 2021;22(21):11365.
19. Ellis JA, Kemp AS, Ponsonby AL, et al. Gene–environment interaction in autoimmune disease. Expert Rev Mol Med. 2014:16:e4.
20. Selmi C. Autoimmunity in 2018. Clin Rev Allergy Immunol. 2019;56(3):375-384.
21. Dong Y, Wong JSL, Sugimora R, et al. Recent advances and future prospects in immune checkpoint (ICI)-based combination therapy for advanced HCC. Cancers (Basel). 2021;13(8):1949.
22. Kraehenbuehl L, Weng CH, Eghbali Sh, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37-50.
23. Beheshti SA, Shamsasenjan K, Ahmadi M, et al. CAR Treg: A new approach in the treatment of autoimmune diseases. Int Immunopharmacol. 2022:102:108409.
24. Murphy AJ, Febbraio MA. Immune-based therapies in cardiovascular and metabolic diseases: past, present and future. Nat Rev Immunol. 2021;21(10):669-679.
25. Wu X, Deng Z, Zhao Q. Immunotherapy improves disease prognosis by affecting the tumor microenvironment: a bibliometric study. Front Immunol. 2022:13:967076.
26. Guder C, Gravious S, Burger CH, et al. Osteoimmunology: a current update of the interplay between bone and the immune system. Front Immunol. 2020:11:58.
27. Sengupta, S. et al. Immunomodulation in autoimmune disorders. In Immunomodulators and Human Health 303–327 (Springer, 2022).
28. Coventry BJ. Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. Ther Adv Vaccines Immunother. 2019:7:2515135519862234.
29. Wan M, Ding L, Wang D, et al. Serotonin: a potent immune cell modulator in autoimmune diseases. Front Immunol. 2020:11:186.
30. Mintz J, Vedenko A, Rosete O, et al., Current advances of nitric oxide in cancer and anticancer therapeutics. Vaccines (Basel). 2021;9(2):94.
31. Virtanen AT, Haikarainen T, Raivola J, et al. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1): 15-32.
32. Li HB, Yang ZH, Guo QQ. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Commun Signal. 2021;19(1):117.
| Files | ||
| Issue | Vol 19 No 4 (2025) | |
| Section | Review Article(s) | |
| Keywords | ||
| Autoimmune diseases; Cancer; Immunity; Immune checkpoints; Cytokines; Immunotherapy; Chronic | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
